Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 6/20 | 0.77 |
| ▸ | MMP9 | P14780 | 6/20 | 0.77 |
| ▸ | MMP3 | P08254 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | APEX1 | P27695 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 2/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenobarbital SCHEMBL18825042 | 0.98 | MMP2 (0.80) | MMP2MMP9MMP3KMT2AMEN1 | |
| Phenobarbital SCHEMBL2592325 | 0.98 | MMP2 (0.80) | MMP2MMP9MMP3KMT2AMEN1 | |
| Phenobarbital SCHEMBL28099657 | 0.98 | MMP2 (0.80) | MMP2MMP9MMP3KMT2AMEN1 | |
| Phenobarbital SCHEMBL16583 | 0.98 | MMP2 (0.80) | MMP2MMP9MMP3KMT2AMEN1 | |
| Phenobarbital SCHEMBL6807467 | 0.96 | MMP2 (0.77) | MMP2MMP9MMP3KMT2AMEN1 | |
| Phenobarbital SCHEMBL22032658 | 0.96 | MMP2 (0.77) | MMP2MMP9MMP3KMT2AMEN1 | |
| Phenobarbital SCHEMBL4193755 | 0.96 | MMP2 (0.77) | MMP2MMP9MMP3KMT2AMEN1 | |
| Phenobarbital SCHEMBL1322895 | 0.96 | MMP2 (0.77) | MMP2MMP9MMP3KMT2AMEN1 | |
| Phenobarbital SCHEMBL3475428 | 0.96 | MMP2 (0.77) | MMP2MMP9MMP3KMT2AMEN1 | |
| Phenobarbital SCHEMBL2120028 | 0.96 | MMP2 (0.77) | MMP2MMP9MMP3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11865103-B2 | Methods of treating disorders associated with glycosylation defective proteins | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-01-09 | — | — | US | claimed |
| US-20220168269-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH GLYCOSYLATION DEFECTIVE PROTEINS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-02 | — | — | US | claimed |
| US-11110076-B2 | Methods of treating disorders associated with glycosylation defective proteins | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-09-07 | — | — | US | claimed |
| US-20200179333-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH GLYCOSYLATION DEFECTIVE PROTEINS | CASE WESTERN RESERVE UNIVERSITY | 2020-06-11 | — | — | US | claimed |
| EP-3773744-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DOMINANTLY-INHERITED CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA | ISTITUTI CLINICI SCIENT MAUGERI S P A S B (IT) | 2024-05-22 | — | — | EP | disclosed |
| EP-4356727-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DOMINANTLY-INHERITED CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA | Istituti Clinici Scientifici Maugeri S.p.A. S.B. (IT) | 2024-04-24 | — | — | EP | disclosed |
| US-20240067974-A1 | METHOD OF ALLELE SPECIFIC SILENCING FOR THE TREATMENT OF AUTOSOMAL DOMINANT CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT) | ISTITUTI CLINICI SCIENT MAUGERI SPA SB (IT) | 2024-02-29 | — | — | US | disclosed |
| US-20240023813-A1 | SYSTEMS AND METHODS FOR ULTRASOUND AND PHOTOACOUSTIC GUIDANCE OF CORONARY PROCEDURES | RESEARCH DEVELOPMENT FOUNDATION (US) | 2024-01-25 | — | — | US | disclosed |
| US-11865103-B2 | Methods of treating disorders associated with glycosylation defective proteins | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | OPTIKIRA LLC (US) | 2023-10-19 | — | — | US | disclosed |
| CN-111526877-B | Compounds and compositions for IRE1 inhibition | 奥普提卡拉公司 | 2023-08-25 | — | — | CN | disclosed |
| EP-4210565-A1 | SYSTEMS AND METHODS FOR ULTRASOUND AND PHOTOACOUSTIC GUIDANCE OF CORONARY PROCEDURES | Research Development Foundation (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-1469717-A2 | TRIPLE TRANSGENIC MOUSE MODEL OF ALZHEIMER'S DISEASE | The Regents of The University of California (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-1331932-A2 | THERAPEUTIC USES FOR IP 3? RECEPTOR-MEDIATED CALCIUM CHANNEL MODULATORS | Contrimmune Biotechnology Inc. (CA) | 2003-08-06 | — | — | EP | disclosed |
| WO-2003053136-A2 | TRIPLE TRANSGENIC MOUSE MODEL OF ALZHEIMER'S DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-07-03 | — | — | WO | disclosed |
| US-6461865-B1 | HOMOZYGOUS OR HETEROZYGOUS MUTATION | DEDHAR SHOUKAT (CA) | 2002-10-08 | — | — | US | disclosed |
| US-20020107193-A1 | Therapeutic uses for IP3 receptor-mediated calcium channel modulators | CONTRIMMUNE BIOTECHNOLOGY INC. (CA) | 2002-08-08 | — | — | US | disclosed |
| WO-2002038140-A2 | THERAPEUTIC USES FOR IP3 RECEPTOR-MEDIATED CALCIUM CHANNEL MODULATORS | CONTRIMMUNE BIOTECHNOLOGY INC (CA) | 2002-05-16 | — | — | WO | disclosed |
| EP-0977831-A1 | CALRETICULIN-DEFICIENT CELLS | SHRINERS HOSPITALS FOR CHILDREN (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998048003-A1 | CALRETICULIN-DEFICIENT CELLS | SHRINERS HOSPITAL FOR CHILDREN (US) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11110076-B2 | Methods of treating disorders associated with glycosylation defective proteins | MAN1B1, MAN2B1, GBA3 | MMP2 2849/4885MMP9 4451/4885MMP3 2897/4885 |
| US-20220168269-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH GLYCOSYLATION DEFECTIVE PROTEINS | MAN1B1, MAN2B1, GBA3 | MMP2 2849/4885MMP9 4451/4885MMP3 2897/4885 |
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | XBP1, ERN1, ERN2 | MMP2 3235/4885MMP9 3166/4885MMP3 2764/4885 |
| US-11865103-B2 | Methods of treating disorders associated with glycosylation defective proteins | MAN1B1, MAN2B1, GBA3 | MMP2 2849/4885MMP9 4451/4885MMP3 2897/4885 |
| US-20200179333-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH GLYCOSYLATION DEFECTIVE PROTEINS | MAN1B1, MAN2B1, GBA3 | MMP2 2849/4885MMP9 4451/4885MMP3 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.